Ignacio IllÃ;n-Gala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4989762/publications.pdf

Version: 2024-02-01

69 papers 1,599 citations

304743 22 h-index 36 g-index

75 all docs

75 docs citations

75 times ranked 2656 citing authors

#	Article	IF	CITATIONS
1	The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	6.2	18
2	Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimer's Research and Therapy, 2022, 14, 27.	6.2	10
3	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	10.8	7
4	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
5	Genotype–Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Frontiers in Neurology, 2022, 13, 861585.	2.4	3
6	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	3.1	8
7	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. Aphasiology, 2021, 35, 240-266.	2.2	7
8	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
9	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. Journal of Neurology, 2021, 268, 3400-3408.	3.6	12
10	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
11	Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 85, 63-68.	2.2	6
12	Specific cortical and subcortical grey matter regions are associated with insomnia severity. PLoS ONE, 2021, 16, e0252076.	2.5	12
13	Selective vulnerability to atrophy in sporadic Creutzfeldtâ€Jakob disease. Annals of Clinical and Translational Neurology, 2021, 8, 1183-1199.	3.7	4
14	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
15	Association of Apolipoprotein E $\acute{\rm E}$ Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	9.0	32
16	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84
17	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	2.4	6
18	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, .	0.8	4

#	Article	lF	CITATIONS
19	Lateâ€onset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
20	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration, 2021, 10, 50.	8.0	32
21	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
22	Calsynteninâ€1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.8	1
23	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
24	Cortical microstructure in the amyotrophic lateral sclerosis–frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.1	19
25	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7
26	Tracking neurodegeneration in frontotemporal dementia and Alzheimer's disease: A comparative study of plasma tau and neurofilament light chain. Alzheimer's and Dementia, 2020, 16, e040015.	0.8	0
27	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. Alzheimer's and Dementia, 2020, 16, e041500.	0.8	0
28	Impact of cortical and subcortical atrophy in the diagnosis and prognosis of bvFTD: A multicenter longitudinal study. Alzheimer's and Dementia, 2020, 16, e044984.	0.8	0
29	Which preâ€nalytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. Alzheimer's and Dementia, 2020, 16, e045060.	0.8	0
30	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	3.3	26
31	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	13.7	164
32	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2020, 12, 603790.	3.4	17
33	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	3.7	44
34	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
35	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Scientific Reports, 2019, 9, 7803.	3.3	33
36	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45

#	Article	IF	CITATIONS
37	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementi 2019, 15, P558.	ia o.8	O
38	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
39	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	3.1	21
40	Elevated YKL-40 and low sAPPÎ ² :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	1.9	17
41	Challenges associated with biomarkerâ€based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	2.4	37
42	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	9.0	54
43	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
44	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the <i>C9orf72</i> expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	1.9	44
45	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	O
46	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF AI MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	LL 0.8	0
47	P1â€277: CORRELATION BETWEEN INNOTEST® AND THE FULLY AUTOMATED LUMIPULSE® G PLATFORM FOR ANALYSIS OF βâ€AMYLOID 1â€42 AND TOTAL TAU. Alzheimer's and Dementia, 2018, 14, P388.	THE 6.8	1
48	CSF sAPPÎ ² , YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.1	59
49	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.8	O
50	P2â€⊋30: CHALLENGES ASSOCIATED WITH BIOMARKERâ€BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P756.	0.8	0
51	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Journal of Alzheimer's Disease, 2018, 64, 505-513.	2.6	16
52	Prion disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 441-464.	1.8	24
53	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
54	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4

#	Article	IF	Citations
55	Evolución a largo plazo de la hidrocefalia crónica del adulto idiopática tratada con válvula de derivación ventrÃculo-peritoneal. NeurologÃa, 2017, 32, 205-212.	0.7	9
56	Long-term outcomes of adult chronic idiopathic hydrocephalus treated with a ventriculo-peritoneal shunt. NeurologÃa (English Edition), 2017, 32, 205-212.	0.4	5
57	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
58	Diagnostic and Prognostic Value ofÂtheÂCombination of Two Measures ofÂVerbal Memory in Mild Cognitive Impairment dueÂto Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 909-918.	2.6	28
59	CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.1	100
60	Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 36-69.	1.7	79
61	[P1–366]: WEIGHT LOSS MIGHT BE A NONâ€COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.8	0
62	The pitfalls of biomarkerâ€based classification schemes. Alzheimer's and Dementia, 2017, 13, 1072-1074.	0.8	5
63	[P1–238]: THE SAPPβ/YKLâ€40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPO LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	ORAL 0.8	0
64	[P4–505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. Alzheimer's and Dementia, 2017, 13, P1533.	0.8	0
65	[P2–259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P71	2. ^{0.8}	0
66	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Oncotarget, 2017, 8, 104706-104716.	1.8	51
67	Effect of anticoagulation on cardioembolic stroke severity, outcomes and response to intravenous thrombolysis. Journal of Thrombosis and Thrombolysis, 2016, 42, 99-106.	2.1	3
68	Recurrence of stroke amongst women of reproductive age: impact of and on subsequent pregnancies. European Journal of Neurology, 2015, 22, 681.	3.3	14
69	Nonconvulsive status epilepticus secondary to paclitaxel administration. Epilepsy & Behavior Case Reports, 2015, 4, 20-22.	1.5	13